We are live on ! Find out more
RGNX icon

Regenxbio

166 hedge funds and large institutions have $784M invested in Regenxbio in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 65 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $3.64M | Put options by funds: $2.54M

2.6% less ownership

Funds ownership: 78.89%76.29% (-2.6%)

7% less funds holding

Funds holding: 179166 (-13)

23% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 65

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

28% less capital invested

Capital invested by funds: $1.08B → $784M (-$298M)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
166
Holders Change
-13
Holders Change %
-7.26%
% of All Funds
3.35%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
19
Increased
50
Reduced
65
Closed
31
Calls
$3.64M
Puts
$2.54M
Net Calls
+$1.1M
Net Calls Change
+$410K
Name Holding Trade Value Shares
Change
Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$6.09M -$938K -28,786 -12%
Charles Schwab
27
Charles Schwab
California
$5.61M -$390K -11,948 -6%
Ameriprise
28
Ameriprise
Minnesota
$5.53M -$1M -30,726 -13%
Citigroup
29
Citigroup
New York
$5.45M +$5.06M +155,091 +362%
FM
30
Frazier Management
Washington
$4.79M +$5.68M +174,200 New
MWNA
31
Marshall Wace North America
New York
$4.73M -$5.71M -175,199 -50%
Invesco
32
Invesco
Georgia
$4.63M -$439K -13,464 -7%
Macquarie Group
33
Macquarie Group
Australia
$4.13M
CG
34
Carmignac Gestion
France
$4.02M -$886K -27,164 -16%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$3.73M +$926K +28,398 +27%
GH
36
GAM Holding
Switzerland
$3.73M +$985K +30,200 +29%
N
37
Nuveen
North Carolina
$3.62M -$405K -12,426 -9%
BCM
38
Burrage Capital Management
Massachusetts
$3.2M +$45.8K +1,405 +1%
First Manhattan
39
First Manhattan
New York
$2.73M +$418K +12,835 +15%
Legal & General Group
40
Legal & General Group
United Kingdom
$2.72M -$153K -4,701 -5%
SG Americas Securities
41
SG Americas Securities
New York
$2.25M +$2.35M +71,974 +749%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$2.09M -$347K -10,648 -12%
DekaBank Deutsche Girozentrale
43
DekaBank Deutsche Girozentrale
Germany
$2.09M +$2.48M +76,000 New
PAWC
44
P.A.W. Capital
Connecticut
$2.06M +$163K +5,000 +7%
GTC
45
Ghost Tree Capital
New York
$2.06M +$2.45M +75,000 New
Bank of America
46
Bank of America
North Carolina
$2.02M -$1.62M -49,591 -40%
Barclays
47
Barclays
United Kingdom
$1.98M -$561K -17,194 -19%
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.97M +$39.1K +1,200 +2%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.95M +$65.2K +2,000 +3%
Citadel Advisors
50
Citadel Advisors
Florida
$1.9M +$460K +14,115 +26%

RGNX Hedge Fund Activity: Q3 2020 in Review

166 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2020, worth a combined $784M — down 28% from $1.08B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RGNX and 19 opened new positions — a net loss of 12 holders — while 65 trimmed existing stakes and 50 added.

The largest buyer was UBS Group, adding an estimated $11.8M. The largest seller was Wellington Management Group, cutting an estimated $9.86M.

  • 166 institutional investors held Regenxbio (RGNX) as of Q3 2020, down from 179 in Q2 2020.
  • Funds reported $784M of Regenxbio stock for Q3 2020, down 28% quarter-over-quarter.
  • 19 funds opened new Regenxbio positions in Q3 2020 and 31 closed out, a net change of -12 holders.
  • The largest Regenxbio buyer in Q3 2020 was UBS Group, an estimated $11.8M added.
  • The largest Regenxbio seller in Q3 2020 was Wellington Management Group, an estimated $9.86M sold.

Based on aggregated 13F filings for Q3 2020.